Impact of time to start systemic therapy on the outcomes of patients with metastatic colorectal cancer treated with first line FOLFOX chemotherapy; a patient-level pooled analysis of two clinical trials.

CONCLUSION: While numerous baseline characteristics play an important role in determining the outcomes of mCRC patients receiving first-line FOLFOX chemotherapy, time to start systemic therapy does not appear to play a pivotal role. PMID: 30099922 [PubMed - as supplied by publisher]
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research